Evaluating real-world experiences of patients treated with BRIUMVI® for relapsing multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and effectiveness of BRIUMVI® (ublituximab-xiiy) in patients diagnosed with relapsing multiple sclerosis (RMS). It focuses on gathering insights into the treatment experiences of participants who have been prescribed this medication in a real-world setting. Participants will be monitored for their health outcomes and any side effects following their first infusion of BRIUMVI®. The study does not involve any experimental interventions, as it is designed to observe the existing treatment protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Confirmed Multiple Sclerosis (MS) diagnosis.
2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.

Exclusion Criteria:

1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

Where it's running

• TG Therapeutics Investigational Trial Site
  Birmingham, Alabama, United States Recruiting
• TG Therapeutics Investigational Trial Site
  Cullman, Alabama, United States Recruiting
• TG Therapeutics Investigational Trial Site
  Huntsville, Alabama, United States Recruiting
• TG Therapeutics Investigational Trial Site
  Mobile, Alabama, United States Recruiting
• TG Therapeutics Investigational Trial Site
  Gilbert, Arizona, United States Recruiting
• TG Therapeutics Investigational Trial Site
  Phoenix, Arizona, United States Recruiting

+63 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: TG Therapeutics Clinical Support Team
• Email: clinicalsupport@tgtxinc.com
• Phone: 1-877-575-8489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ublituximab in MS: how injection site and delivery method affect absorption

  This study tests how different SC injection sites and a prefilled pen delivery compare in how ublituximab behaves in the body for people with relapsing MS.

  Recruiting at 44 sites Phase 2 TG Therapeutics, Inc. · Bihać and 43 other locations · NCT07503873

• Switching to ublituximab for ocrelizumab wearing-off in multiple sclerosis

  This pilot will try switching people with relapsing MS who experience symptom 'wearing off' on ocrelizumab to ublituximab to see if their symptoms improve or return later.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07389590

• Ublituximab (Briumvi) for early relapsing MS

  This study will test whether giving Ublituximab (Briumvi) about twice a year is safe and changes a blood marker (neurofilament light) in adults with early relapsing MS.

  Recruiting Phase 4 Northwestern University · Chicago, Illinois · NCT07225361

• Ublituximab in Pediatric Relapsing MS: See if a B-cell therapy works in kids

  This study tests whether ublituximab can work in children and teens with relapsing MS and compares it to fingolimod in eligible participants.

  Recruiting at 5 sites Phase 2/3 TG Therapeutics, Inc. · Salt Lake City, Utah and 5 other locations · NCT07220252

• Evaluating a modified treatment regimen of ublituximab for relapsing multiple sclerosis

  This study is testing a new way to use ublituximab to see if it can help people with relapsing multiple sclerosis feel better and stay safe.

  Recruiting at 49 sites Phase 3 TG Therapeutics, Inc. · Birmingham, Alabama and 50 other locations · NCT05877963

• Treadmill-based virtual reality walking training for MS patients

  This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.

  Recruiting Shepherd Center, Atlanta GA · Atlanta, Georgia · NCT07927439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.